Press Releases
2020
- August 5 Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- June 1 Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona®（PDF）
- May 29 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- May 15 JT Files for Additional Indication for Riona®, Ferric Citrate Hydrate, for Iron Deficiency Anemia in Japan（PDF）
- April 22 Listing on the NHI Drug Price List and Launch of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- March 18 Company Spin-Off (Short-Form Absorption-Type Company Split) and Share Transfer of a Newly Founded Subsidiary with Transfer of Sakura Plant（PDF）
- February 6 Progress of the Medium-Term Management Plan 2021 and Revision of the Targets（PDF）
- January 23 JT Receives Manufacturing and Marketing Approval of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- January 15 Torii Signs Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan（PDF）
2019
- November 29 JT Files New Drug Application of Enarodustat (JTZ-951), for the Treatment of Anemia Associated with CKD in Japan（PDF）
- November 25 Transfer of rights to uricosuric agent URINORM®（PDF）
- November 5 Torii has entered into a License Agreement with BioCryst Pharmaceuticals, Inc. for BCX7353 for the prevention of HAE attacks（PDF）
- September 2 JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan to Gilead Sciences K.K.（PDF）
- July 12 Top-line Results of Phase 3 Clinical Studies of JTZ-951 (enarodustat),in Anemic Patients with Chronic Kidney Disease(Comparative Study) in Japan（PDF）
- July 9 Top-line Results of Phase 3 Clinical Study of Riona®, (ferric citrate hydrate), in Adult Patients with Iron Deficiency Anemia (Comparative Study) in Japan（PDF）
- June 17 Results of Voluntary Retirement Program（PDF）
- May 30 Implementation of Organizational Reform（PDF）
- April 25 Top-line Results of JTE-052 Ointment, JAK inhibitor, Phase 3 Clinical Study in Pediatric Patients with Atopic Dermatitis (Comparative Study) in Japan（PDF）
- March 1 A Presentation on the Phase 3 Clinical Study (Comparative Study) of JTE-052 Ointment, JAK Inhibitor, at the 2019 AAD annual meeting（PDF）
- February 6 Torii has announced the Medium-Term Management Plan 2021（PDF）
- February 6 TRANSFER OF RIGHTS TO protease inhibitor FUTHAN® for injection（PDF）
- January 31 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Atopic Dermatitis in Japan（PDF）
2018
- December 14 The date for terminating the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan has been set（PDF）
- November 29 Torii has agreed with JT to terminate the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan（PDF）
- August 27 JT Signs a Letter of Intent to Initiate Discussion to Terminate Agreements on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan（PDF）
- June 28 JT and Torii Discontinue Development of NK-1 Receptor Antagonist (JTS-661) and Terminate Exclusive License Agreement with Menlo Therapeutics（PDF）
- May 24 Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- April 18 Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- February 16 Torii receives approval for additional dosage and administration for pediatric indication for MITICURE® House Dust Mite Sublingual Tablets, an Allergen Immunotherapy Tablet for House Dust Mite Allergy（PDF）
- January 12 Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan（PDF）
Older press releases can be found in the Back Number.